Grifols Has Acquired Talecris Biotherapeutics
Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, has completed acquisition of Talecris Biotherapeutics. They will now operate under the company name Grifols.
"The union of our two companies provides an infusion of energy and talent, and strengthens our commitment to our shared mission of providing life-saving therapies to patients with rare, chronic diseases," said Victor Grifols, President and CEO of Grifols. "The strength of our combined company is not simply its size; rather, it is the potential to achieve more for patients in the future than either company would be able to accomplish on its own."